Literature DB >> 1311411

A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase.

I Hide1, W L Padgett, K A Jacobson, J W Daly.   

Abstract

Binding assays and assays of activation of adenylate cyclase with the agonists 5'-N-ethylcarboxyamidoadenosine (NECA) and CGS21680 have been used to compare adenosine receptors in rat pheochromocytoma PC12 cells and in rat striatum. The [3H]NECA binding showed two components, whereas [3H]CGS21680 bound to one component in both tissues. The Kd value for the high affinity site labeled with [3H]NECA in PC12 cell membranes (2.3 nM) was lower than that in striatum (6.5 nM). The [3H]CGS21680 binding site showed a Kd value of 6.7 nM and 11.3 nM in PC12 cells and striatum, respectively. In the presence of GTP the KD values of [3H]NECA and [3H]CGS21680 for the high affinity site were increased severalfold, whereas the low affinity sites for [3H]NECA were no longer detected with filtration assays. A comparison of the ability of a series of agonists and antagonists to inhibit high affinity binding of [3H]NECA to A2 receptors in PC12 cell and striatal membranes indicated that agonists had higher affinities and antagonists had lower affinities in PC12 cells, compared with affinities in striatal membranes. Analysis of activation of adenylate cyclase in PC12 cell membranes suggested that the dose-dependent stimulation by NECA involved two components, whereas CGS21680 stimulated via one component. The maximal stimulation by NECA significantly exceeded that caused by CGS21680. In intact PC12 cells, NECA caused a greater accumulation of AMP than did CGS21680, as was the case in membranes. In striatal membranes, NECA and CGS21680 showed similar maximal stimulations of adenylate cyclase. Both NECA and CGS21680 were more potent in PC12 cell membranes than in striatal membranes, in agreement with binding data. However, in contrast to binding data, antagonists were not less potent versus stimulation of adenylate cyclase by NECA or CGS21680 in PC12 cell membranes, compared with striatal membranes. In toto, the results suggest that A2A receptors in striatum are virtually identical to the A2A receptors in PC12 cells. But, in addition to an A2A receptor, it appears that a lower affinity functional receptor, probably an A2B receptor, is present in PC12 cells and PC12 cell membranes, whereas such a functional low affinity receptor is not detectable in striatal membrane.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311411      PMCID: PMC4523143     

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  33 in total

1.  RDC8 codes for an adenosine A2 receptor with physiological constitutive activity.

Authors:  C Maenhaut; J Van Sande; F Libert; M Abramowicz; M Parmentier; J J Vanderhaegen; J E Dumont; G Vassart; S Schiffmann
Journal:  Biochem Biophys Res Commun       Date:  1990-12-31       Impact factor: 3.575

2.  5'-N-ethylcarboxamido[8-3H]adenosine binds to two different adenosine receptors in membranes from the cerebral cortex of the rat.

Authors:  C Florio; U Traversa; R Vertua; P Puppini
Journal:  Neuropharmacology       Date:  1988-01       Impact factor: 5.250

3.  Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts.

Authors:  R F Bruns
Journal:  Biochem Pharmacol       Date:  1981-02-15       Impact factor: 5.858

4.  Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cells.

Authors:  D Ukena; J W Daly; K L Kirk; K A Jacobson
Journal:  Life Sci       Date:  1986-03-03       Impact factor: 5.037

5.  Agonist derived molecular probes for A2 adenosine receptors.

Authors:  K A Jacobson; L K Pannell; X D Ji; M F Jarvis; M Williams; A J Hutchison; W W Barrington; G L Stiles
Journal:  J Mol Recognit       Date:  1989-12       Impact factor: 2.137

6.  Adenosine binding sites of rat pheochromocytoma PC 12 cell membranes: partial characterization and solubilization.

Authors:  H Nakata; H Fujisawa
Journal:  J Biochem       Date:  1988-09       Impact factor: 3.387

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.

Authors:  M T Shamim; D Ukena; W L Padgett; J W Daly
Journal:  J Med Chem       Date:  1989-06       Impact factor: 7.446

9.  Caffeine analogs: structure-activity relationships at adenosine receptors.

Authors:  J W Daly; I Hide; C E Müller; M Shamim
Journal:  Pharmacology       Date:  1991       Impact factor: 2.547

10.  CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity.

Authors:  A J Hutchison; R L Webb; H H Oei; G R Ghai; M B Zimmerman; M Williams
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

View more
  36 in total

1.  [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors.

Authors:  X Ji; Y C Kim; D G Ahern; J Linden; K A Jacobson
Journal:  Biochem Pharmacol       Date:  2001-03-15       Impact factor: 5.858

2.  Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors.

Authors:  X D Ji; K A Jacobson
Journal:  Drug Des Discov       Date:  1999-11

3.  A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.

Authors:  J E Nash; J M Brotchie
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

4.  Functional characterization of adenosine A2 receptors in Jurkat cells and PC12 cells using adenosine receptor agonists.

Authors:  I van der Ploeg; S Ahlberg; F E Parkinson; R A Olsson; B B Fredholm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

5.  Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors.

Authors:  R A Cunha; B Johansson; M D Constantino; A M Sebastião; B B Fredholm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

6.  Chemical modification and irreversible inhibition of striatal A2a adenosine receptors.

Authors:  K A Jacobson; G L Stiles; X D Ji
Journal:  Mol Pharmacol       Date:  1992-07       Impact factor: 4.436

7.  2-[2-[4-[2-[2-[ 1,3-Dihydro- 1,1-bis (4-hydroxyphenyl)-3-oxo-5-isobenzofuranthioureidyl]ethylaminocarbonyl]ethyl]phenyl] ethylamino]-5'-N-ethylcarboxamidoadenosine (FITC-APEC): A Fluorescent Ligand For A2a-Adenosine Receptors.

Authors:  R Tyler McCabe; Phil Skolnick; Kenneth A Jacobson
Journal:  J Fluoresc       Date:  1992-12       Impact factor: 2.217

8.  Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.

Authors:  Andreas A Erdmann; Zhan-Guo Gao; Unsu Jung; Jason Foley; Todd Borenstein; Kenneth A Jacobson; Daniel H Fowler
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

9.  Adenosine receptor-mediated modulation of acetylcholine release from rat striatal synaptosomes.

Authors:  K A Kirkpatrick; P J Richardson
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

10.  Activation of adenosine A2A or A2B receptors causes hypothermia in mice.

Authors:  Jesse Lea Carlin; Shalini Jain; Romain Duroux; R Rama Suresh; Cuiying Xiao; John A Auchampach; Kenneth A Jacobson; Oksana Gavrilova; Marc L Reitman
Journal:  Neuropharmacology       Date:  2018-03-13       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.